| scholarly article | Q13442814 |
| P5530 | Altmetric DOI | 10.1016/S1470-2045(17)30318-2 |
| P6409 | CORE ID | 153791437 |
| P6179 | Dimensions Publication ID | 1086085229 |
| P356 | DOI | 10.1016/S1470-2045(17)30318-2 |
| P953 | full work available at URL | http://eprints.whiterose.ac.uk/117960/ |
| P932 | PMC publication ID | 5555437 |
| P698 | PubMed publication ID | 28642008 |
| P1154 | Scopus EID | 2-s2.0-85020944773 |
| P50 | author | Pierre Fournel | Q56424312 |
| Jason Pantarotto | Q56424313 | ||
| Penella Woll | Q57474508 | ||
| Jan Van Meerbeeck | Q91985767 | ||
| Paul Lorigan | Q32649737 | ||
| Corinne Faivre-Finn | Q37830473 | ||
| Fiona Blackhall | Q37831554 | ||
| P2093 | author name string | Felipe Cardenal | |
| Andrea Bezjak | |||
| Jan P Van Meerbeeck | |||
| Linda Ashcroft | |||
| Mary O'Brien | |||
| Fabrice Barlesi | |||
| Michael Snee | |||
| Cecile Le Pechoux | |||
| Rhona McMenemin | |||
| Veerle Surmont | |||
| Susan Harden | |||
| Nazia Mohammed | |||
| Adityanarayan Bhatnagar | |||
| CONVERT Study Team | |||
| Wiebke Appel | |||
| P2860 | cites work | Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. | Q50789972 |
| The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. | Q53189764 | ||
| Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer | Q57618367 | ||
| Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide | Q77912158 | ||
| Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer | Q24245945 | ||
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis | Q30248898 | ||
| Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer | Q33504330 | ||
| Keynote address on biostatistics and data retrieval. | Q34213509 | ||
| Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis | Q35091203 | ||
| A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer | Q35961932 | ||
| Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer | Q35966667 | ||
| Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer | Q36339439 | ||
| Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with lim | Q36526895 | ||
| Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey | Q37498889 | ||
| A meta-analysis of thoracic radiotherapy for small-cell lung cancer | Q41086687 | ||
| Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis | Q45371243 | ||
| Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group | Q48341719 | ||
| Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. | Q48477176 | ||
| Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine | Q49102895 | ||
| P433 | issue | 8 | |
| P921 | main subject | chemoradiotherapy | Q5090613 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 1116-1125 | |
| P577 | publication date | 2017-06-19 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial | |
| P478 | volume | 18 |
| Q90016420 | 18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial |
| Q92862797 | A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials |
| Q57806334 | A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients |
| Q62851605 | Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. |
| Q92111378 | Association of Twice-Daily Radiotherapy With Subsequent Brain Metastases in Adults With Small Cell Lung Cancer |
| Q93334895 | Bracing for impact with new 4R's in the COVID-19 pandemic- a provincial thoracic radiation oncology consensus |
| Q50060045 | CONVERTed or not: what are the barriers to implementing the evidence? |
| Q50060039 | CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply |
| Q91844914 | Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer |
| Q52587549 | Comparing Treatment Strategies for Stage I Small-cell lung Cancer. |
| Q55516294 | Comparison and discussion of the treatment guidelines for small cell lung cancer. |
| Q58574211 | Compliance and outcome of elderly patients treated in the Concurrent ONce daily VErsus twice-daily RadioTherapy (CONVERT) trial |
| Q49978476 | Concurrent once-daily or twice-daily chemoradiotherapy in limited-stage small-cell lung cancer? |
| Q98226197 | Current Management and Progress in Radiotherapy for Small Cell Lung Cancer |
| Q47989130 | Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer |
| Q54953051 | Current standards for clinical management of small cell lung cancer. |
| Q91243409 | Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses |
| Q92356134 | Heart V5 predicts cardiac events in unresectable lung cancer patients undergoing chemoradiation |
| Q92236896 | Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges |
| Q55093161 | Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer. |
| Q91724678 | Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review |
| Q57785727 | Interim Analysis of a Two-Institution, Prospective Clinical Trial of 4DCT-Ventilation-based Functional Avoidance Radiation Therapy |
| Q95405638 | Is it time to convert the frequency of radiotherapy in small-cell lung cancer? |
| Q50261220 | Is it time to convert the frequency of radiotherapy in small-cell lung cancer? |
| Q89129779 | Is it time to convert the frequency of radiotherapy in small-cell lung cancer? |
| Q50261212 | Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply |
| Q99603504 | Neutrophil-to-lymphocyte ratio can predict outcome in extensive-stage small cell lung cancer |
| Q55062496 | No room for statins in the quest for survival benefits in small cell lung cancer. |
| Q60926671 | Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis |
| Q91742354 | Patterns of care and survival outcomes for laryngeal small cell cancer |
| Q89947460 | Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer |
| Q56528378 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
| Q55079973 | Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. |
| Q90290807 | Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial |
| Q55358944 | Proton therapy for small cell lung cancer. |
| Q50139034 | Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis |
| Q55038620 | Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't! |
| Q94592974 | Radiotherapy in Lung Cancer: Current and Future Role |
| Q98467055 | Radiotherapy target volume for limited-disease small cell lung cancer: good news from the dark side of the moon |
| Q94672120 | Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic |
| Q47115640 | Research in imaging/biomarkers for precision medicine in lung cancer: National Cancer Institute funding opportunities |
| Q89630996 | SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) |
| Q91638654 | Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer |
| Q92072927 | Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients |
| Q55023905 | Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. |
| Q64084792 | Spatially Specific Liposomal Cancer Therapy Triggered by Clinical External Sources of Energy |
| Q49207460 | Surgery for small cell lung cancer in the modern era: opportunities and challenges |
| Q49886142 | The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer. |
| Q41605002 | The clinical utility of circulating tumour cells in patients with small cell lung cancer |
| Q52672760 | The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. |
| Q58804836 | The evolving role of radiotherapy in the management of small cell lung cancer |
| Q61804643 | The optimal treatment approaches for stage I small cell lung cancer |
| Q92136222 | Thoracic radiation therapy during COVID-19: provisional guidelines from a comprehensive cancer center within a pandemic epicenter |
| Q95295671 | Treatment guidance for lung cancer patients during the COVID-19 pandemic |
| Q92382555 | Treatment time to the end of thoracic radiotherapy has more predictive power for survival than radiation dose intensity in patients with limited-stage small-cell lung cancer receiving concurrent chemoradiation of more than 45 Gy |
| Q47153324 | Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer |
| Q53705076 | Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer? |
| Q91326771 | Will liquid biopsies improve outcomes for patients with small-cell lung cancer? |
Search more.